Lilly ' s Bamlanivimab with Etesevimab Authorized as the First and Only Neutralizing Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12

INDIANAPOLIS, Dec. 3, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab administered together to include certain high-risk pediatric patients from...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials